# Nasdaq:RVMD news releases

Nasdaq:RVMD press releases distributed through HARO Newswire to the journalists who cover the beat.

- **Releases in the last 90 days:** 584
- **Web page:** https://www.helpareporter.com/news-releases/nasdaqrvmd
- **RSS:** https://www.helpareporter.com/news-releases/nasdaqrvmd/rss.xml

### [Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026](https://www.helpareporter.com/news-releases/revolution-medicines-presents-updated-phase-12-data-for-rasonquer-2)

November 20, 2026 · Revolution Medicines · Nasdaq:RVMD

With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve…
